Search Press releases Keywords From To 24 Jan 2022 BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma Read More 21 Jan 2022 Disposals of own shares Read More 21 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Read More 19 Jan 2022 UCB to acquire Zogenix Read More 18 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study Read More 8 Jan 2022 Disposals of own shares Read More Pagination First page Previous page Previous … Page 47 Page 48 Page 49 Page 50 Current page 51 Page 52 Page 53 Page 54 Page 55 … Page 51 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
